Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 12Genitourinary 4Dermatologic 4Other hematologic neoplasm 3Gastrointestinal 3Thoracic 2Plasma cell 2Head & Neck 2Gynecologic 2Endocrine 2Sarcoma 1Myeloid 1Classical hematology 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 1Lung Neoplasms 1Genetic Diseases, Inborn 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × romidepsin × Thoracic × Clear all
NCT00020202 2024-03-04

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Genetic Diseases, Inborn, Small Cell Lung Carcinoma

NCT00086827 2014-04-10

Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡